Eric Crombez Sells 16,284 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Eric Crombez sold 16,284 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $5.09, for a total transaction of $82,885.56. Following the completion of the sale, the director owned 63,456 shares of the company’s stock, valued at approximately $322,991.04. The trade was a 20.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Abeona Therapeutics Trading Up 1.9%

Shares of ABEO opened at $5.27 on Wednesday. The stock’s 50-day moving average price is $5.17 and its 200 day moving average price is $5.58. The company has a quick ratio of 9.53, a current ratio of 9.74 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $285.58 million, a price-to-earnings ratio of 4.28 and a beta of 1.18. Abeona Therapeutics Inc. has a 12-month low of $3.93 and a 12-month high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. As a group, research analysts predict that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.

Abeona Therapeutics News Roundup

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: Institutional buying: multiple funds disclosed new or larger stakes in ABEO (AIGH Capital Management, Aberdeen Group among others), signaling professional investor interest that can support the share price. MarketBeat Institutional Trading
• Positive Sentiment: Recent quarter topped expectations: Abeona reported -$0.10 EPS vs. Street -$0.27 on Nov. 12, which is a positive fundamental surprise for a clinical-stage biotech that can lift sentiment. Earnings Recap
• Positive Sentiment: Balance sheet and liquidity appear strong (high current and quick ratios, low debt-to-equity), reducing near-term financing risk for clinical programs — a positive for risk-sensitive investors. Financials
• Neutral Sentiment: Analyst landscape is mixed but tilted positive: several buy ratings and an average target materially above the current price (MarketBeat cites an average target near $20), though opinions vary. Analyst Notes
• Neutral Sentiment: Inclusion on retail/investor lists: Abeona appeared in a Yahoo Finance roundup of “Insider-Favored Growth Companies To Watch,” which can boost visibility but is not a fundamental catalyst by itself. Yahoo Article
• Neutral Sentiment: Short-interest notes show effectively zero reported short interest and a 0.0 days-to-cover figure in recent reports — likely a reporting artifact and not meaningful market pressure at present.
• Negative Sentiment: Insider selling: several directors sold shares on Feb. 2 (Leila Alland sold 18,065 shares; Eric Crombez sold 16,284 shares; Mark Alvino sold 2,000 shares). Large or clustered director sales can weigh on sentiment even if they may be liquidity-driven. Recent filings: SEC/InsiderTrades disclosures. InsiderTrades Article SEC Filing

Wall Street Analysts Forecast Growth

ABEO has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a research note on Monday, October 13th. Finally, Wall Street Zen lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Abeona Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Institutional Trading of Abeona Therapeutics

Large investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. acquired a new stake in shares of Abeona Therapeutics during the second quarter worth approximately $25,000. Legal & General Group Plc bought a new stake in Abeona Therapeutics during the 2nd quarter worth approximately $27,000. Russell Investments Group Ltd. acquired a new stake in Abeona Therapeutics during the 3rd quarter valued at $37,000. SG Americas Securities LLC acquired a new stake in Abeona Therapeutics during the 4th quarter valued at $57,000. Finally, Legato Capital Management LLC bought a new position in Abeona Therapeutics in the 3rd quarter valued at $57,000. 80.56% of the stock is owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.